Karyopharm Therapeutics Inc. Announced earnings guidance for the year 2023. Based on its current operating plans, Karyopharm is updating its guidance for full year 2023: Total revenue to be in the range of $145 million to $160 million. Total revenue consists of U.S. XPOVIO net product revenue and license, royalty and milestone revenue earned from partners.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.13 USD | +4.63% | +6.60% | +30.64% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+30.64% | 126M | |
-1.43% | 103B | |
+8.96% | 101B | |
+4.40% | 23.07B | |
-12.15% | 22.23B | |
-4.36% | 18.05B | |
-39.98% | 17.18B | |
-10.04% | 16.94B | |
+6.79% | 14.07B | |
+38.61% | 12.35B |
- Stock Market
- Equities
- KPTI Stock
- News Karyopharm Therapeutics Inc.
- Karyopharm Therapeutics Inc. Announces Earnings Guidance for the Year 2023